Alembic Pharmaceuticals on Tuesday informed the exchanges that it has received tentative nod from the US health regulator for its Alogliptin tablets used for treatment of type 2 diabetes.
The company has received tentative approval from the US Food and Drug Administration for its Alogliptin tablets in the strengths of 6.25 mg, 12.5 mg and 25 mg, Alembic Pharma said in the filing.
The product is the generic version of Takeda Pharma USA’s Nesina tablets of the same strengths, it added. The tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, Alembic Pharma said. Shares of Alembic Pharma, after hitting the day’s high of ₹613, closed at ₹599.60, up 0.63 per cent, over the previous day’s close.